Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 226 results for "Tecfidera Treated Patients"

New Data from ENDORSE Show Positive Results Continued over Fiv...

Long-term Favorable Safety Profile Sustained in Patients Treated with TECFIDERA Positive Clinical and MRI Outcomes in Newly Diagnosed Patients CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 11, 2014-- Today Biogen Idec (NASDAQ: BIIB) announced that ... BusinessWeek, 2 weeks ago

2 images for "Tecfidera Treated Patients"

ABC News 4 Charleston, 2 months ago
Global News Canada, 5 months ago

New oral MS treatment Tecfidera approved for use in England and Wales

Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in England and Wales, the National Institute for Health and Care Excellence (NICE) has announced. The NHS must now begin funding this treatment for eligible ...
 Multiple Sclerosis Society1 month ago

Making Treatment Decisions When There Is an Abundance of Options

Despite the benefit of having more choices than ever before to treat patients with multiple sclerosis (MS), the abundance of options has led to more complexity, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, ...
 American Journal of Managed Care2 weeks ago Multiple Sclerosis Drugs Could Transform Market Again  Investor's Business Daily4 days ago New Biogen MS drug challenges Copaxone  Globes1 month ago

TECFIDERA, a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta

MISSISSAUGA, ON, Aug. 7, 2014 /CNW/ -Biogen Idec Canada announces today that Alberta Health will now reimburse TECFIDERA (dimethyl fumarate) through the Alberta Drug Benefit List (DBL). TECFIDERA is a first-line oral treatment for adults with ...
 MoneyShow.com1 month ago TECFIDERA(tm), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed  Finwin1 month ago
Bioresearch Online

Biogen Idec Announces Strides In Clinical Studies For MS Treatments

By Lori Clapper Biogen Idec announced clinical study results for three of its Multiple Sclerosis (MS) treatments at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European ...
 Bioresearch Online1 week ago NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)  FirstWord Pharma1 month ago FDA approves new injectable multiple sclerosis treatment from Cambridge's Biogen Idec  Boston Globe1 month ago Why Biogen Stock Is Still An Investment Opportunity  Seeking Alpha1 week ago

5 Things Biogen Idec Inc's Management Wants You to Know

1."Our core multiple sclerosis franchise performed remarkably well, and we continue to see an increasing number of patients using our therapies." -- George Scangos, Biogen Idec's CEO When Biogen Idec launched its oral multiple sclerosis drug ...
 Motley Fool4 weeks ago
Boston Globe

FDA okays Genzyme pill for Gaucher disease

Federal regulators Tuesday okayed for US sale a Genzyme experimental capsule that could become the top-selling pill to treat the rare genetic disorder Gaucher disease. Food and Drug Administration approval of the drug candidate, called Cerdelga, ...
 Boston Globe1 month ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 1, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago

The Launch of Five Immunomodulatory Therapies for Relapsing Forms of Multiple Sclerosis Will Contribute to 4 Percent Annual Growth of the Total Market from 2013 to 2023

Biogen Idec's Tecfidera is Forecast to Overtake Teva's Copaxone Franchise as the U.S. Market Leader by 2015 According to Findings from Decision Resources Group PR Newswire BURLINGTON Mass. Aug. 7 2014BURLINGTON Mass. Aug. 7 2014 /PRNewswire/ -- ...
 PharmiWeb1 month ago

Orphan drugs may be pricey, but payers are barely balking

Some orphan drugs to treat rare diseases can cost as much as $400,000 a year. Those hefty price tags have sparked a lively debate in recent years about whether the American health care system can shoulder the burden of treating rare diseases over ...
 FiercePharma6 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less